Evidence map›Paper›PMID 30645699›Full record

ArticleInvestigational new drugs2019

The cellular effects of novel triazine nitrogen mustards in glioblastoma LBC3, LN-18 and LN-229 cell lines.

Rafał Krętowski, Danuta Drozdowska, Beata Kolesińska, Zbigniew Kamiński, Justyna Frączyk, Marzanna Cechowska-Pasko

Open access · hybridAbstract read
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rafał KrętowskiDepartment of Pharmaceutical Biochemistry, Medical University of Bialystok, Bialystok, Poland.
Danuta DrozdowskaDepartment of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland.
Beata KolesińskaInstitute of Organic Chemistry, Technical University of Lodz, Lodz, Poland.
Zbigniew KamińskiInstitute of Organic Chemistry, Technical University of Lodz, Lodz, Poland.
Justyna FrączykInstitute of Organic Chemistry, Technical University of Lodz, Lodz, Poland.
Marzanna Cechowska-PaskoDepartment of Pharmaceutical Biochemistry, Medical University of Bialystok, Bialystok, Poland. mapasko@gmail.com.ORCID 0000-0002-2806-399X
Lodz University of Technology · PLMedical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1,3,5-triazine is an important heterocyclic skeleton for mono, two or three 2-chloroethylamine groups. The study presented here provides novel information on cellular effects of 1,3,5-triazine with mono, two or three 2-chloroethylamine groups in glioblastoma LBC3, LN-18 and LN-229 cell lines. In our study, the most cytotoxic effect was observed in 1,3,5-triazine with three 2-chloroethylamine groups (12f compound). It has been demonstrated that 12f induce time- and dose-dependent cytotoxicity in all investigated glioma cell lines. Apart from that in glioblastoma cells, treated with 12f compound, we noticed strong induction of apoptosis. In conclusion, this research provides novel information concerning cellular effects of apoptosis in LBC3, LN-18 and LN-229 cell lines. Moreover, we suggest that 12f compound may be a candidate for further evaluation as an effective chemotherapeutic agent for human glioblastoma cells.

Indexed as

Antineoplastic AgentsApoptosisCell ProliferationGlioblastomaHumansNecrosisNitrogen Mustard CompoundsTriazinesTumor Cells, CulturedAntineoplastic AgentsNitrogen Mustard CompoundsTriazinesAlkylating agentApoptosisGlioblastomaHybrid anticancer drugsNitrogen mustard

Identifiers

PMID30645699
PMCPMC6736897
OpenAlexW2909803083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.